Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study

Although immune checkpoint inhibitor therapy has led to modest response rates in patients with advanced urothelial cancer, the combination of chemotherapy with immune checkpoint inhibition has not been previously clinically studied. In this phase I study, we found that the combination of pembrolizum...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Genitourin Cancer
Egile Nagusiak: Parikh, Mamta, Pan, Chong-Xian, Beckett, Laurel A., Li, Yueju, Robles, Daniel A., Aujla, Pawandeep K., Lara, Primo N.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6450697/
https://ncbi.nlm.nih.gov/pubmed/30166228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.07.004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak